## **Core Concept**
The question tests knowledge of antiplatelet drugs, specifically those that act as P2Y12 receptor blockers and their pharmacogenetic profiles regarding CYP2C19 polymorphism. P2Y12 receptor blockers are crucial in preventing thrombotic events in patients with cardiovascular diseases.

## **Why the Correct Answer is Right**
Ticagrelor is a P2Y12 receptor blocker that does not require metabolic activation by the liver and thus is not affected by CYP2C19 polymorphism. Unlike clopidogrel, which is a prodrug that needs to be metabolized by CYP2C19 to its active form, ticagrelor's mechanism does not rely on this metabolic pathway. This makes ticagrelor's efficacy more consistent across different populations, regardless of their CYP2C19 genotype.

## **Why Each Wrong Option is Incorrect**
- **Option A: Clopidogrel** is incorrect because its metabolism to the active form is significantly influenced by CYP2C19 polymorphism. Poor metabolizers have reduced efficacy of clopidogrel.
- **Option B: Prasugrel** is incorrect because, although it is less affected by CYP2C19 polymorphism compared to clopidogrel, it still undergoes some degree of metabolism that could potentially be influenced by genetic variations.
- **Option D: Tirofiban** is incorrect because it is a glycoprotein IIb/IIIa inhibitor and not a P2Y12 receptor blocker, making it irrelevant to the question about P2Y12 receptor blockers.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that ticagrelor, due to its pharmacokinetic profile, offers a consistent antiplatelet effect without the variability seen with clopidogrel in relation to CYP2C19 polymorphism. This makes ticagrelor a preferred option in patients who are poor metabolizers of clopidogrel.

## **Correct Answer: . Ticagrelor**